Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts
Summary
Tango Therapeutics has an exciting new opportunity for an experienced and innovative translational scientist in our Translational Medicine Team, to lead clinical biomarker development, in vitro diagnostic and companion diagnostic activities in support of ongoing clinical trials. This role will drive cross functional collaboration among discovery biologists, translational scientists, clinical operations, data management, regulatory, clinical compliance and quality groups to deliver biomarker insights to clinical development teams. Additionally, this position will administer operational aspects of clinical biomarker assays in clinical trials, including management of internal and external translational collaborations, third party laboratories and other clinical partners.
Your Role
- Oversee design, development, validation, verification and implementation of translational and clinical-grade biomarker assays to inform essential clinical research questions
- Compile clinical biomarker assay data, conduct in-stream analyses, and package those translational insights for communication to key stakeholders throughout the clinical development organization
- Author and contribute content to biomarker plans and clinical study protocols
- Execute risk management of novel clinical biomarker assays, managing oversight and quality control of pre-analytic, analytic, and post-analytic assay components
- Perform technical assessments of existing and novel clinical biomarker assays and assay platforms for suitability, validity, clinical utility, robustness, and feasibility to meet business objectives
- Identify and vet translational and clinical biomarker assay vendors according to Tango’s GxP processes
- Manage relationships with third party vendors to ensure clinical biomarker assay outputs are delivered on-time, on-budget, and on-target to meet or exceed functional requirements and business objectives
- Install data transfer specifications with clinical biomarker assay laboratories, working in partnership with Tango’s clinical data management organization
- Contribute scientific expertise and biomarker data analysis in support of IVD regulatory submissions
- Contribute to optimization of translational medicine business process infrastructure
- Additional duties and responsibilities as required
What You Bring
- Advanced degree in biological sciences or related, with at least 5 years relevant translational clinical experience in biopharma
- Experience in oncology drug development
- Track record of developing successful translational clinical assets in a biopharma setting
- Demonstrated proficiency in clinical biomarker data generation, aggregation and analysis
- Demonstrated facility in a GxP setting
- Familiarity with domestic and/or international regulatory review and approval of IVD assays
- Outstanding analytical skills, a highly organized approach and exceptional attention to detail
- Proven track record as a collaborative team player, with superior communication style and well-developed interpersonal skills
- Ability to thrive in an interdisciplinary setting across pre-clinical and clinical development arenas, and with colleagues at all levels
This is a hybrid/flexible role!
#LI-Hybrid
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
What We Do
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
